52 week high was 27.64 so this is not over valued with expected q2 earnings. I think we will see $30 before July 4 and if earnings are good it will move north.
Sure I'm being exuberant, but I think there's a real shot: that's roughly a $3bn valuation. All that has to happen is that some institutional investors start to believe that Omidria will eventually grow to become standard of use in cataract surgery. The short squeeze will serve to accelerate the rise in price.
Sentiment: Strong Buy
the rise in pps today probably has nothing to do with Omeros - virtually EVERY biotec stock is up today.
As the previous topic said, there are 8.4m shares that don't want your prediction to happen.
I think Q2 sales will be strong. Per prior CC some of the sales staff started calling during August 2014. The additional 20 sales staff started going to the field late Jan (the initial sales staff of 20 were in the field prior to Jan 2015). I think the ramp-up has already occurred (per prior CC they will target the physician groups and individual docs that perform majority of the operations).
Alan Ross ? He is a great musician. Bought 4 cds recently. He started together with Eric Clapton then moved apart.
Yes currently OMER market cap is over double from last May 30. Last May the median market cap of the Russell 2000 was $713m, so at close to $1B our ranking in the index will be much higher. We will need to double again to get close to moving up to the Russell 1,000 index. With the massive collapse of small/mid cap energy companies and the stellar rise of biotechs it would be nice if OMER replaces one of those stocks in other indexes.
Just checked and may 29 is correct , That will give us an extra month for EMA approval and have you checked past years when our market cap is higher than previous year , how much OMER appreciates the month of June?
The Doc said 2nd quarter and he sounded very sure about it , I would love to see it before Russell index rebalance cause that initiates on May 1, Omer market cap will be much larger than last year which will mean that many more shares will have to be purchased during May
Sentiment: Strong Buy
First of all, fantastic find, moreomerrome! Quite subtle. But I see that Omidria was on the corresponding document from, for example, back in October; and it was mentioned in the meeting minutes from January, but only as a postponement. (Searched Google for "phenylephrine ketorolac chmp") Do you see any reason to think that April will be different from other recent months? I hope you're right!
30 Churchill Place
Send a question via our website
An agency of the European Union
© European Medicines Agency,
. Reproduction is authorised provided the source is acknowledged.
7 April 2015
tion Management Division
Applications for new human medicines under evaluation
by the Committee for Medicinal Products for Human Use